Page 3 - Biologics Proof News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Biologics proof. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Biologics Proof Today - Breaking & Trending Today

Nanoform Interim Report January – June 2021

Nanoform Interim Report January – June 2021
di.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from di.se Daily Mail and Mail on Sunday newspapers.

San Diego , United States , Eteläuomen Läi , United Kingdom , Celanese Vitaldose , Christian Jones , Chris Worral , Miguel Calado , Biologics Po , Master Services Agreement , Vp Business Development , Finnish Financial Supervisory Authority , Boehringer Ingelheim , European Biotech Company , Nacuity Pharmaceuticals , Finland Branch , Danske Bank , Coast Us Biotech Company , Celanese Corporation , Nanoform Finland Plc , Herantis Pharma Plc , Company Announcement , Interim Report January , Biologics Proof , Concept Agreement , Biologics Poc ,

Nanoform Interim Report January

/PRNewswire/ The strong momentum continues: Additional line capacity, more projects, new clients, the number of employees crosses 100, while the gross. ....

Eteläuomen Läi , San Diego , United States , United Kingdom , Celanese Vitaldose , Christian Jones , Chris Worral , Miguel Calado , Biologics Po , Master Services Agreement , Vp Business Development , Boehringer Ingelheim , European Biotech Company , Nacuity Pharmaceuticals , Finland Branch , Danske Bank , Coast Us Biotech Company , Celanese Corporation , Herantis Pharma Plc , Biologics Proof , Concept Agreement , Biologics Poc , East Coast , Commercial Insights Officer , Oxford United Kingdom , European Biotech ,

Nanoform Interim Report January – March (Q1) 2021

Nanoform Interim Report January – March (Q1) 2021
Nanoform
Company Announcement
Nanoform Interim Report January – March (Q1) 2021
Strong momentum continues: three new non-GMP lines commissioned, four new clients signed, and six new customer PoC projects commenced. In addition, positive results from
first clinical study announced, two near-term business targets achieved (“First Biologics PoC in 2021” and “at least three new non-GMP lines in 2021”), next generation STARMAP
® launched, EUR 40 million successfully raised and commercial teams in the US and the UK further strengthened.
1-3/2021 key financials
- Revenue EUR 278 thousand, growth + 85%, stemming from 14 different customer projects (EUR 150 thousand, 6 customer projects in 1-3/2020).
- The gross profit and gross margin improved to EUR 243 thousand and 88%, respectively (EUR 103 thousand, 68%). ....

Eteläuomen Läi , San Diego , United States , United Kingdom , Celanese Vitaldose , Chris Worral , Miguel Calado , Biologics Po , Vp Business Development , Finnish Financial Supervisory Authority , European Biotech Company , Nacuity Pharmaceuticals , Finland Branch , Danske Bank , Coast Us Biotech Company , Celanese Corporation , Nanoform Finland Plc , Herantis Pharma Plc , Company Announcement , Interim Report January , Biologics Poc , Biologics Proof , Concept Agreement , East Coast , Commercial Insights Officer , Oxford United Kingdom ,

Nanoform 1-12/2020 report and new company near-term target introduced

Nanoform 1-12/2020 report and new company near-term target introduced
Nanoform
Company Announcement
Nanoform 1-12/2020 report and new company near-term target introduced
First GMP manufacturing campaign and first dosing in humans successfully completed, positive interim results from first clinical study announced, all near-term business targets set out in IPO achieved, ten new Small Molecule PoC projects started, four more non-GMP lines commissioned, first Biologics PoC project commenced and a new near-term business target introduced: “At least 3 new non-GMP lines in 2021 and 2 new GMP lines in 2022”.
10-12/2020 key financials:
- Revenue was EUR 186 thousand (EUR 49 thousand in 10-12/2019).
- The gross profit and margin came in at EUR 135 thousand and 73%, during 10-12/2019 the gross profit was negative. ....

Eteläuomen Läi , United States , United Kingdom , April Nanoform , Johanna Tuomisto , Eric Peter , Miguel Calado , July Nanoform , Biologics Po , Sergie Letser , Christian Jones , Cynthia Schwalm , June Nanoform , Finnish Financial Supervisory Authority , Finnish Medicines Agency , Finland Branch , Orion Corporation , Nanoform United States Inc , Danske Bank , Coast Us Biotech Company , Nanoform Finland Plc , Herantis Pharma Plc , Company Announcement , Small Molecule Poc , Biologics Poc , January Nanoform United States ,

Nanoform and Herantis sign Biologics Proof of Concept Agreement

HELSINKI, Feb. 9, 2021 /PRNewswire/ Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc, an innovative . ....

Eteläuomen Läi , Christian Jones , Craig Cook , Biologics Po , Herantis Pharma , Danske Bank , Prnewswire Nanoform Finland Plc , Us Patent Office , Finnish Financial Supervisory Authority , Finland Branch , Herantis Pharma Plc , Finland Plc , Biologics Proof , Concept Agreement , Biologics Poc , Chief Commercial Officer , Chief Executive Officer , Nasdaq First North Growth Market , Certified Adviser , Pharma Plc , Nasdaq First North Growth Market Finland , Looking Statements , கிறிஸ்துவர் ஜோன்ஸ் , கிரேக் சமைக்கவும் , உயிரியல் போ , எங்களுக்கு காப்புரிமை அலுவலகம் ,